Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin

Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investig. 2001;19(4):424–36.

Pawan K, Singal NI. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900–5.

Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990;4(13):3076–86.

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and Cardiotoxicity. Pharmacol Rev. 2004;56:185–229.

Charrois G, Allen T. Multiple injections of Pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther. 2003;306(3):1058–67.

Judson I, Radford JA, Harris M, Blay JY, Van Hoesel Q, Le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2001;37(7):870–7.

Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet. 2003;42(5):419–36.

Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102.

Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1–9.

Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;154:987–92.

Amit B, Zehavi U, Patchornik A. Photosensitive protecting groups of amino sugars and their use in glycoside synthesis. 2-Nitrobenzyloxycarbonylamino and 6-Nitroveratryloxycarbonylamino derivatives. J Org Chem. 1974;39:192–6.

Ibsen S, Zahavy E, Wrasidlo W, Berns M, Chan M, Esener S. A novel doxorubicin Prodrug with controllable photolysis activation for cancer chemotherapy. Pharm Res. 2010;27(9):1848–60.

Ibsen S, Zahavy E, Wrasidlo W, Hayashi T, Norton J, Su Y, et al. Localized in-vivo activation of a Photoactivatable doxorubicin Prodrug in deep tumor tissue. Photochem Photobiol. 2013;89:698–708.

Tietze LF, Neumann M, Mollers T, Fischer R, Glusenkamp KH, Rajewsky MF, et al. Proton-mediated liberation of Aldophosphamide from a nontoxic Prodrug: a strategy for tumor-selective activation of Cytocidal drugs. Cancer Res. 1989;49:4179–84.

Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–47.

Breistol K, Hendriks HR, Berger DP, Langdon SP, Fiebig HH, Fodstad O. The antitumour activity of the Prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour Xenografts. Eur J Cancer. 1998;34(10):1602–6.

Gopin A, Ebner S, Attali B, Shabat D. Enzymatic activation of second-generation dendritic prodrugs: conjugation of self-immolative dendrimers with PEG via click chemistry. Bioconjug Chem. 2006;17:1432–40.

Shamis M, Lode HN, Shabat D. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. JACS. 2004;126:1726–31.

Park J, Hong K, Kirpotin D, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 Immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8:1172–81.

Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–65.

Ni T, Baudisch P. Disappearing mobile devices. In: Proceedings of the 22nd annual ACM symposium on user interface software and technology Victoria. British Columbia, Canada: Association for Computing Machinery; 2009. p. 101–10.

Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34(8):1274–81.

Yang Y, Celmer EJ, Koutcher JA, Alfano RR. UV reflectance spectroscopy probes DNA and protein changes in human breast tissues. J Clin Laser Med Surg. 2001;19(1):35–9.

Sutherland J, Griffin K. Absorption Spectrum of DNA for wavelengths greater than 300 nm. Radiat Res. 1981;86(3):399–410.

Elisseeff J, Anseth K, Sims D, McIntosh W, Randolph M, Langer R. Transdermal photopolymerization for minimally invasive implantation. Proc Natl Acad Sci. 1999;96:3104–7.

Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99–105.

Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target. 2002;10(7):539–48.

Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther. 2004;308(2):419–25.

Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med. 2002;8(12):563–71.

Quigley GJ, Wang AH, Ughetto G, van der Marel G, van Boom JH, Rich A. Molecular structure of an anticancer drug-DNA complex: Daunomycin plus d(CpGpTpApCpG). Proc Nati Acad Sc USA. 1980;77(12):7204–8.

Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the Anthracycline antibiotics Adriamycin and Daunorubicin. Biochem Pharmacol. 1999;57:727–41.

Botvinick EL, Berns MW. Internet based robotic laser scissors and tweezers microscopy. Microsc Res Tech. 2005;68(2):65–74.